Skip to main content
SpringerLink
Log in

Use of Ghrelin and Ghrelin Receptor Agonists in Cancer- and Chemotherapy-Induced Cachexia

  • Chapter
  • First Online:
Ghrelin in Health and Disease

Part of the book series: Contemporary Endocrinology ((COE,volume 10))

  • 921 Accesses

Abstract

The Cancer Anorexia-Cachexia Syndrome (CACS) is present in up to 80% of cancer patients decreasing their quality of life and survival. Nevertheless, treatments for this condition are lacking. Ghrelin and its mimetics appear promising in the treatment of CACS. Ghrelin increases growth hormone/IGF-1 levels, body weight, and appetite, and decreases energy expenditure in healthy subjects. Also, animal and human studies have shown favorable anabolic effects of ghrelin in the setting of cancer. In preliminary studies, anamorelin, an orally available ghrelin mimetic, also seems to improve weight loss in cancer cachexia patients. Furthermore, in animal models of cisplatin-induced cachexia and emesis, ghrelin infusion stabilizes appetite, increases weight, and improves GI side effects. In several short-term studies ghrelin was found to be safe; however, long-term safety of ghrelin and ghrelin mimetics has not yet been fully established. In summary, more studies are needed looking into the long-term safety and efficacy of ghrelin and its mimetics in cancer patients and other chronic diseases associated with cachexia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793–9.

    Article  PubMed  CAS  Google Scholar 

  2. Laviano A, Meguid MM. Nutritional issues in cancer management. Nutrition. 1996;12:358–71.

    Article  PubMed  CAS  Google Scholar 

  3. Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage. 2007;34:94–104.

    Article  PubMed  Google Scholar 

  4. Maltoni M, Nanni O, Pirovano M, et al. Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. J Pain Symptom Manage. 1999;17:240–7.

    Article  PubMed  CAS  Google Scholar 

  5. Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg. 1994; 219:325–31.

    Article  PubMed  CAS  Google Scholar 

  6. McGeer AJ, Detsky AS, O’Rourke K. Parenteral nutrition in cancer patients undergoing chemotherapy: a meta-analysis. Nutrition. 1990;6:233–40.

    PubMed  CAS  Google Scholar 

  7. Cohn SH, Gartenhaus W, Sawitsky A, et al. Compartmental body composition of cancer patients by measurement of total body nitrogen, potassium, and water. Metabolism. 1981; 30:222–9.

    Article  PubMed  CAS  Google Scholar 

  8. Zuijdgeest-van Leeuwen SD, van den Berg JW, Wattimena JL, et al. Lipolysis and lipid oxidation in weight-losing cancer patients and healthy subjects. Metabolism. 2000;49:931–6.

    Article  PubMed  CAS  Google Scholar 

  9. Jatoi A, Daly BD, Hughes VA, Dallal GE, Kehayias J, Roubenoff R. Do patients with nonmetastatic non-small cell lung cancer demonstrate altered resting energy expenditure? Ann Thorac Surg. 2001;72:348–51.

    Article  PubMed  CAS  Google Scholar 

  10. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69:491–7.

    Article  PubMed  CAS  Google Scholar 

  11. Levine JA, Morgan MY. Preservation of macronutrient preferences in cancer anorexia. Br J Cancer. 1998;78:579–81.

    Article  PubMed  CAS  Google Scholar 

  12. Staal-van den Brekel AJ, Schols AM, ten Velde GP, Buurman WA, Wouters EF. Analysis of the energy balance in lung cancer patients. Cancer Res. 1994;54:6430–3.

    PubMed  CAS  Google Scholar 

  13. Donthireddy KR, Ailawadhi S, Nasser E, et al. Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol. 2007;5:355–63.

    PubMed  CAS  Google Scholar 

  14. Tocco-Bradley R, Georgieff M, Jones CT, et al. Changes in energy expenditure and fat metabolism in rats infused with interleukin-1. Eur J Clin Invest. 1987;17:504–10.

    Article  PubMed  CAS  Google Scholar 

  15. Van der Poll T, Romijn JA, Endert E, Borm JJ, Buller HR, Sauerwein HP. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol. 1991;261:E457–65.

    PubMed  Google Scholar 

  16. Sonti G, Ilyin SE, Plata-Salaman CR. Anorexia induced by cytokine interactions at pathophysiological concentrations. Am J Physiol. 1996;270:R1394–402.

    PubMed  CAS  Google Scholar 

  17. Wallenius K, Wallenius V, Sunter D, Dickson SL, Jansson JO. Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem Biophys Res Commun. 2002;293:560–5.

    Article  PubMed  CAS  Google Scholar 

  18. Lyngso D, Simonsen L, Bulow J. Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J Physiol. 2002;543:379–86.

    Article  PubMed  CAS  Google Scholar 

  19. Asakawa A, Inui A, Kaga T, et al. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology. 2001;120:337–45.

    Article  PubMed  CAS  Google Scholar 

  20. Walsh D, Mahmoud F, Barna B. Assessment of nutritional status and prognosis in advanced cancer: interleukin-6, C-reactive protein, and the prognostic and inflammatory nutritional index. Support Care Cancer. 2003;11:60–2.

    Article  PubMed  Google Scholar 

  21. Mantovani G, Maccio A, Mura L, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med. 2000;78:554–61.

    Article  PubMed  CAS  Google Scholar 

  22. Garcia JM, Garcia-Touza M, Hijazi RA, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab. 2005;90:2920–6.

    Article  PubMed  CAS  Google Scholar 

  23. Garcia JM, Li H, Mann D, et al. Hypogonadism in male patients with cancer. Cancer. 2006;106:2583–91.

    Article  PubMed  CAS  Google Scholar 

  24. Sutton LM, Demark-Wahnefried W, Clipp EC. Management of terminal cancer in elderly patients. Lancet Oncol. 2003;4:149–57.

    Article  PubMed  Google Scholar 

  25. Kotler DP. Cachexia. Ann Intern Med. 2000;133:622–34.

    PubMed  CAS  Google Scholar 

  26. Pascual Lopez A, Roque i Figuls M, Urrutia Cuchi G, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage. 2004; 27:360–9.

    Article  PubMed  Google Scholar 

  27. Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs. 1998;55:675–88.

    Article  PubMed  CAS  Google Scholar 

  28. Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol. 2006;24:3394–400.

    Article  PubMed  CAS  Google Scholar 

  29. Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer. 1990;65:2657–62.

    Article  PubMed  CAS  Google Scholar 

  30. Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol. 2004;22:2469–76.

    Article  PubMed  CAS  Google Scholar 

  31. Fearon KC, Barber MD, Moses AG, et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol. 2006;24: 3401–7.

    Article  PubMed  CAS  Google Scholar 

  32. Goldberg RM, Loprinzi CL, Mailliard JA, et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol. 1995; 13:2856–9.

    PubMed  CAS  Google Scholar 

  33. Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut. 2005;54:540–5.

    Article  PubMed  CAS  Google Scholar 

  34. Bruera E, Belzile M, Neumann C, Harsanyi Z, Babul N, Darke A. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage. 2000;19:427–35.

    Article  PubMed  CAS  Google Scholar 

  35. Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol. 1999;17:3299–306.

    PubMed  CAS  Google Scholar 

  36. Edelman MJ, Gandara DR, Meyers FJ, et al. Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome. Cancer. 1999;86:684–8.

    Article  PubMed  CAS  Google Scholar 

  37. Lundholm K, Korner U, Gunnebo L, et al. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin Cancer Res. 2007;13:2699–706.

    Article  PubMed  CAS  Google Scholar 

  38. Mantovani G, Maccio A, Madeddu C, et al. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med. 2010; 88:85–92.

    Article  PubMed  CAS  Google Scholar 

  39. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–60.

    Article  PubMed  CAS  Google Scholar 

  40. Smith RG, Van der Ploeg LH, Howard AD, et al. Peptidomimetic regulation of growth hormone secretion. Endocrinol Rev. 1997;18:621–45.

    Article  CAS  Google Scholar 

  41. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623–30.

    Article  PubMed  Google Scholar 

  42. Granado M, Priego T, Martin AI, Villanua MA, Lopez-Calderon A. Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab. 2005;288:E486–92.

    Article  PubMed  CAS  Google Scholar 

  43. Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci U S A. 2004;101:4679–84.

    Article  PubMed  CAS  Google Scholar 

  44. Wang Z, Wang W, Qiu W, et al. Involvement of ghrelin-growth hormone secretagogue receptor system in pathoclinical profiles of digestive system cancer. Acta Biochim Biophys Sin (Shanghai). 2007;39:992–8.

    Article  PubMed  CAS  Google Scholar 

  45. Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab. 2000;85:4908–11.

    Article  PubMed  CAS  Google Scholar 

  46. Garcia JM, Polvino WJ. Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res. 2009;19:267–73.

    Article  PubMed  CAS  Google Scholar 

  47. Wren AM, Small CJ, Abbott CR, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes. 2001;50:2540–7.

    Article  PubMed  CAS  Google Scholar 

  48. Garcia JM, Polvino WJ. Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist. 2007;12:594–600.

    Article  PubMed  CAS  Google Scholar 

  49. Murphy MG, Plunkett LM, Gertz BJ, et al. MK-0677, an orally active growth hormone secretagogue reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998;83:320–5.

    Article  PubMed  CAS  Google Scholar 

  50. Vestergaard ET, Djurhuus CB, Gjedsted J, et al. Acute effects of ghrelin administration on glucose and lipid metabolism. J Clin Endocrinol Metab. 2008;93:438–44.

    Article  PubMed  CAS  Google Scholar 

  51. Dixit VD, Schaffer EM, Pyle RS, et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest. 2004; 114:57–66.

    PubMed  CAS  Google Scholar 

  52. Dembinski A, Warzecha Z, Ceranowicz P, et al. Role of growth hormone and insulin-like growth factor-1 in the protective effect of ghrelin in ischemia/reperfusion-induced acute pancreatitis. Growth Horm IGF Res. 2006;16:348–56.

    Article  PubMed  CAS  Google Scholar 

  53. Sun Y, Garcia JM, Smith RG. Ghrelin and growth hormone secretagogue receptor expression in mice during aging. Endocrinology. 2007;148:1323–9.

    Article  PubMed  CAS  Google Scholar 

  54. Pardo M, Roca-Rivada A, Al-Massadi O, Seoane LM, Camina JP, Casanueva FF. Peripheral leptin and ghrelin receptors are regulated in a tissue-specific manner in activity-based anorexia. Peptides. 2010;31:1912–9.

    Article  PubMed  CAS  Google Scholar 

  55. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab. 2002;87:2988.

    Article  PubMed  CAS  Google Scholar 

  56. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000; 407:908–13.

    Article  PubMed  CAS  Google Scholar 

  57. Kos K, Harte AL, O’Hare PJ, Kumar S, McTernan PG. Ghrelin and the differential regulation of des-acyl and oct-anoyl ghrelin in human adipose tissue. Clin Endocrinol (Oxf). 2009; 70:383–9.

    Article  CAS  Google Scholar 

  58. Theander-Carrillo C, Wiedmer P, Cettour-Rose P, et al. Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest. 2006;116:1983–93.

    Article  PubMed  CAS  Google Scholar 

  59. Barazzoni R, Bosutti A, Stebel M, et al. Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle. Am J Physiol Endocrinol Metab. 2005;288:E228–35.

    Article  PubMed  CAS  Google Scholar 

  60. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001;294:1704–8.

    Article  PubMed  CAS  Google Scholar 

  61. Yamamoto D, Ikeshita N, Matsubara T, et al. GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1. Life Sci. 2008;82:460–6.

    Article  PubMed  CAS  Google Scholar 

  62. Delhanty PJ, Sun Y, Visser JA, et al. Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice. PLoS One. 2010;5:e11749.

    Article  PubMed  Google Scholar 

  63. Shiiya T, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab. 2002;87:240–4.

    Article  PubMed  CAS  Google Scholar 

  64. Cummings DE, Clement K, Purnell JQ, et al. Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med. 2002;8:643–4.

    Article  PubMed  CAS  Google Scholar 

  65. Soriano-Guillen L, Barrios V, Campos-Barros A, Argente J. Ghrelin levels in obesity and anorexia nervosa: effect of weight reduction or recuperation. J Pediatr. 2004;144:36–42.

    Article  PubMed  CAS  Google Scholar 

  66. Nagaya N, Uematsu M, Kojima M, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation. 2001;104:2034–8.

    Article  PubMed  CAS  Google Scholar 

  67. Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest. 2005;128:1187–93.

    Article  PubMed  CAS  Google Scholar 

  68. Hanada T, Toshinai K, Date Y, et al. Upregulation of ghrelin expression in cachectic nude mice bearing human melanoma cells. Metabolism. 2004;53:84–8.

    Article  PubMed  CAS  Google Scholar 

  69. Wolf I, Sadetzki S, Kanety H, et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer. 2006;106:966–73.

    Article  PubMed  CAS  Google Scholar 

  70. Shimizu Y, Nagaya N, Isobe T, et al. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res. 2003;9:774–8.

    PubMed  CAS  Google Scholar 

  71. Malendowicz W, Ziolkowska A, Szyszka M, Kwias Z. Elevated blood active ghrelin and unaltered total ghrelin and obestatin concentrations in prostate carcinoma. Urol Int. 2009;83: 471–5.

    Article  PubMed  CAS  Google Scholar 

  72. Huang Q, Fan YZ, Ge BJ, Zhu Q, Tu ZY. Circulating ghrelin in patients with gastric or colorectal cancer. Dig Dis Sci. 2007;52:803–9.

    Article  PubMed  CAS  Google Scholar 

  73. D’Onghia V, Leoncini R, Carli R, et al. Circulating gastrin and ghrelin levels in patients with colorectal cancer: correlation with tumour stage, Helicobacter pylori infection and BMI. Biomed Pharmacother. 2007;61:137–41.

    Article  PubMed  Google Scholar 

  74. Hanada T, Toshinai K, Kajimura N, et al. Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem Biophys Res Commun. 2003;301:275–9.

    Article  PubMed  CAS  Google Scholar 

  75. Wang W, Andersson M, Iresjo BM, Lonnroth C, Lundholm K. Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoid-related cachexia. Int J Oncol. 2006;28:1393–400.

    PubMed  CAS  Google Scholar 

  76. DeBoer MD, Zhu XX, Levasseur P, et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology. 2007;148: 3004–12.

    Article  PubMed  CAS  Google Scholar 

  77. Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004; 89:2832–6.

    Article  PubMed  CAS  Google Scholar 

  78. Strasser F, Lutz TA, Maeder MT, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer. 2008;98:300–8.

    Article  PubMed  CAS  Google Scholar 

  79. Lundholm K, Gunnebo L, Korner U, et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer. 2010;116: 2044–52.

    Article  PubMed  CAS  Google Scholar 

  80. Svensson J, Lonn L, Jansson J-O, et al. Two-Month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83:362–9.

    Article  PubMed  CAS  Google Scholar 

  81. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149: 601–11.

    PubMed  Google Scholar 

  82. Cassoni P, Papotti M, Catapano F, et al. Specific binding sites for synthetic growth hormone secretagogues in non-tumoral and neoplastic human thyroid tissue. J Endocrinol. 2000;165: 139–46.

    Article  PubMed  CAS  Google Scholar 

  83. Volante M, Allia E, Fulcheri E, et al. Ghrelin in fetal thyroid and follicular tumors and cell lines: expression and effects on tumor growth. Am J Pathol. 2003;162:645–54.

    Article  PubMed  CAS  Google Scholar 

  84. Cassoni P, Papotti M, Ghe C, et al. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab. 2001;86:1738–45.

    Article  PubMed  CAS  Google Scholar 

  85. Jeffery PL, Herington AC, Chopin LK. Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines. J Endocrinol. 2002;172:R7–11.

    Article  PubMed  CAS  Google Scholar 

  86. Duxbury MS, Waseem T, Ito H, et al. Ghrelin promotes pancreatic adenocarcinoma cellular proliferation and invasiveness. Biochem Biophys Res Commun. 2003;309:464–8.

    Article  PubMed  CAS  Google Scholar 

  87. Wolf RF, Ng B, Weksler B, Burt M, Brennan MF. Effect of growth hormone on tumor and host in an animal model. Ann Surg Oncol. 1994;1:314–20.

    Article  PubMed  CAS  Google Scholar 

  88. Bartlett DL, Charland S, Torosian MH. Growth hormone, insulin, and somatostatin therapy of cancer cachexia. Cancer. 1994;73:1499–504.

    Article  PubMed  CAS  Google Scholar 

  89. Bartlett DL, Stein TP, Torosian MH. Effect of growth hormone and protein intake on tumor growth and host cachexia. Surgery. 1995;117:260–7.

    Article  PubMed  CAS  Google Scholar 

  90. Liu YL, Malik NM, Sanger GJ, Andrews PL. Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents. Cancer Chemother Pharmacol. 2006;58:326–33.

    Article  PubMed  CAS  Google Scholar 

  91. Rudd JA, Ngan MP, Wai MK, et al. Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci Lett. 2006;392:79–83.

    Article  PubMed  CAS  Google Scholar 

  92. Garcia JM, Cata JP, Dougherty PM, Smith RG. Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia. Endocrinology. 2008;149:455–60.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Michael E. DeBakey VA Medical Center, Houston, TX, USA

    Basil Burney M.D.

  2. Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, 2002 Holcombe Blvd, Houston, TX, 77030, USA

    Jose M. Garcia M.D., Ph.D

Authors
  1. Basil Burney M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jose M. Garcia M.D., Ph.D
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jose M. Garcia M.D., Ph.D .

Editor information

Editors and Affiliations

  1. , Department of Metabolism and Aging, The Scripps Research Institute Florida, Scripps Way 3B3 130, Jupiter, 33458, Florida, USA

    Roy G. Smith

  2. , Department of Medicine, University of Virginia, Ray C Hunt Drive 450, Charlottesville, 22908, Virginia, USA

    Michael O. Thorner

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Burney, B., Garcia, J.M. (2012). Use of Ghrelin and Ghrelin Receptor Agonists in Cancer- and Chemotherapy-Induced Cachexia. In: Smith, R., Thorner, M. (eds) Ghrelin in Health and Disease. Contemporary Endocrinology, vol 10. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-903-7_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-903-7_12

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61779-902-0

  • Online ISBN: 978-1-61779-903-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation